Cargando…
Vaccine Uptake in the US After Full Food and Drug Administration Approval of the BNT162b2 mRNA COVID-19 Vaccine
This cross-sectional study examines the association of full approval of the BNT162b2 mRNA vaccine by the US Food and Drug Administration (FDA) with subsequent US uptake of COVID-19 vaccines of any kind.
Autores principales: | Bailey, Elise Vandersteen, Wilson, Fernando A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987898/ https://www.ncbi.nlm.nih.gov/pubmed/35385093 http://dx.doi.org/10.1001/jamanetworkopen.2022.6108 |
Ejemplares similares
-
BNT162b2 mRNA COVID-19 Vaccine: First Approval
por: Lamb, Yvette N.
Publicado: (2021) -
BNT162b2 mRNA Vaccine Interference with Co-Administration of Tdap Vaccine
por: Chilimuri, Sridhar, et al.
Publicado: (2021) -
Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
por: Dickerman, Barbra A., et al.
Publicado: (2021) -
Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccine
por: Ramírez-García, Almudena, et al.
Publicado: (2021) -
Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)